Stigmasterol

Stigmasterol is a plant-derived phytosterol found in soybean oil, rapeseed, and various vegetables that competes with dietary cholesterol for intestinal absorption via the NPC1L1 transporter. Its primary mechanisms include modulation of sterol regulatory element-binding proteins (SREBPs) and inhibition of pro-inflammatory cyclooxygenase pathways.

Origin & History

Stigmasterol is a phytosterol (plant sterol) synthesized via the mevalonate pathway, featuring double bonds at the 5,6- and 22,23-positions. It occurs naturally in soy, calabar beans, and fortified foods like margarines and yogurts, typically extracted using solvent methods to yield a white, water-insoluble powder.

Historical & Cultural Context

No traditional or historical medicinal uses were documented in the research. Current literature focuses exclusively on modern biochemical and pharmacological applications rather than ethnomedical history.

Health Benefits

• Anti-cholesterol effects shown in preclinical studies (evidence: preliminary)
• Antitumor activity via cell cycle arrest and apoptosis induction (evidence: in vitro/in silico)
• Anti-inflammatory properties demonstrated in laboratory settings (evidence: preliminary)
• Potential neuroprotective effects (evidence: preclinical only)
• Antioxidant activity observed in non-human studies (evidence: preliminary)

How It Works

Stigmasterol reduces cholesterol absorption by competing with cholesterol at the Niemann-Pick C1-Like 1 (NPC1L1) transporter in intestinal enterocytes, downregulating SREBP-2-mediated cholesterol synthesis. It exerts anti-inflammatory effects by inhibiting NF-κB signaling and suppressing COX-2 and 5-LOX enzyme activity, reducing prostaglandin and leukotriene production. In cancer cell lines, stigmasterol induces G2/M cell cycle arrest and triggers intrinsic apoptosis via modulation of Bcl-2/Bax protein ratios and caspase-3 activation.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were found in the research dossier. Current evidence is limited to preclinical data including in vitro, animal, and in silico modeling studies showing binding to receptors like ER-α, PR, HER2, and EGFR with affinities of -8.8 to -10 kcal/mol.

Clinical Summary

The majority of evidence for stigmasterol derives from in vitro cell studies and rodent models, with limited randomized controlled human trials isolating its specific effects. Animal studies using doses of 50–200 mg/kg body weight have demonstrated reductions in total cholesterol and LDL-C by up to 30–40% in hypercholesterolemic rodent models. Anti-inflammatory effects have been quantified in murine models showing significant reductions in paw edema and TNF-α levels comparable to indomethacin at equivalent doses. Human evidence is largely extrapolated from broader phytosterol mixture trials, where 2 g/day of mixed plant sterols reduced LDL-C by 8–10%, making isolation of stigmasterol's specific contribution impossible at this stage.

Nutritional Profile

Stigmasterol (C₂₉H₄₈O, MW 412.69 g/mol) is a plant sterol (phytosterol) and is not a macronutrient or food per se, but rather a bioactive lipophilic compound found embedded in the unsaponifiable fraction of plant-derived fats and oils. Key details: • Classification: Δ5,22-unsaturated phytosterol (3β-hydroxy-24-ethylcholesta-5,22-dien-3-ol); differs from β-sitosterol by the presence of a C-22 double bond. • Typical dietary intake: Estimated at 20–50 mg/day in Western diets as part of total phytosterol intake (~200–400 mg/day combined with β-sitosterol, campesterol, etc.); vegetarian/vegan diets may provide higher amounts (up to 60–80 mg/day of stigmasterol specifically). • Rich dietary sources and approximate concentrations: Soybean oil (~50–70 mg/100 g oil), rapeseed/canola oil (~3–10 mg/100 g), unrefined sunflower oil (~30–60 mg/100 g), calabar bean, fava beans (~15–30 mg/100 g dry weight), and various legumes, nuts, and seeds. Also present in some medicinal herbs and vegetables in lower concentrations (1–15 mg/100 g). • Macronutrient contribution: Negligible — stigmasterol is consumed in milligram quantities and contributes virtually no caloric energy, protein, carbohydrate, or dietary fiber. • Bioactive properties: Functions as a competitive inhibitor of intestinal cholesterol absorption via interaction with NPC1L1 transporter and displacement from mixed micelles; modulates membrane fluidity in cell membranes. • Bioavailability: Very low — intestinal absorption of stigmasterol is estimated at only ~0.5–5% (compared to ~40–60% for cholesterol), largely due to active efflux back into the intestinal lumen by ABCG5/ABCG8 sterol transporters. The C-22 unsaturation further reduces absorption relative to saturated-side-chain sterols like β-sitosterol (~5–10%). Absorbed stigmasterol is preferentially excreted in bile. • No vitamins or minerals are intrinsic to the stigmasterol molecule itself. • Solubility note: Highly lipophilic; poorly water-soluble. Bioavailability is enhanced when consumed with dietary fat or when formulated as stigmasterol esters (esterified with fatty acids), microencapsulated, or incorporated into lipid-based delivery systems (nanoemulsions increase apparent bioavailability by 2–4 fold in preclinical models). • Metabolites: Partially converted to stigmasterol glucuronide and other conjugates in the liver; does not serve as a precursor for human steroid hormones but is used industrially as a precursor for semi-synthesis of progesterone and corticosteroids.

Preparation & Dosage

No clinically studied dosage ranges have been established for stigmasterol in humans. The compound is mentioned as a dietary supplement for cholesterol reduction in preclinical contexts, but without specific human dosing data or standardization percentages. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other phytosterols, omega-3 fatty acids, plant stanols, soluble fiber, coenzyme Q10

Safety & Interactions

Stigmasterol is generally considered safe when consumed through dietary sources, but high-dose supplementation has not been rigorously evaluated in long-term human safety trials. Individuals with sitosterolemia, a rare autosomal recessive disorder causing excess phytosterol accumulation, must avoid phytosterol supplements including stigmasterol due to risk of accelerated atherosclerosis. Stigmasterol may potentiate the LDL-lowering effects of statins and ezetimibe, as both target overlapping cholesterol absorption pathways, warranting monitoring if combined. Pregnancy and breastfeeding safety has not been established in controlled studies, and supplemental doses are not recommended during these periods.